45.67
-1.42 (-3.02%)
| Penutupan Terdahulu | 47.09 |
| Buka | 46.89 |
| Jumlah Dagangan | 1,464,472 |
| Purata Dagangan (3B) | 2,218,020 |
| Modal Pasaran | 8,483,430,912 |
| Harga / Pendapatan (P/E Ke hadapan) | 2.50 |
| Harga / Jualan (P/S) | 2.84 |
| Harga / Buku (P/B) | 3.29 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 May 2025 - 12 May 2025 |
| Margin Keuntungan | -37.29% |
| Margin Operasi (TTM) | -4.92% |
| EPS Cair (TTM) | -5.59 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 10.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 115.55% |
| Nisbah Semasa (MRQ) | 2.15 |
| Aliran Tunai Operasi (OCF TTM) | 210.54 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 61.42 M |
| Pulangan Atas Aset (ROA TTM) | -1.87% |
| Pulangan Atas Ekuiti (ROE TTM) | -37.09% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menurun | Menurun |
| Diagnostics & Research (Global) | Menurun | Menurun | |
| Stok | Exact Sciences Corporation | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.13 |
|
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.07% |
| % Dimiliki oleh Institusi | 100.62% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 73.00 (Scotiabank, 59.84%) | Beli |
| Median | 60.00 (31.38%) | |
| Rendah | 52.00 (RBC Capital, 13.86%) | Pegang |
| Purata | 62.14 (36.06%) | |
| Jumlah | 6 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 45.71 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Guggenheim | 11 Apr 2025 | 60.00 (31.38%) | Beli | 42.55 |
| Barclays | 10 Apr 2025 | 55.00 (20.43%) | Beli | 42.55 |
| 20 Feb 2025 | 65.00 (42.33%) | Beli | 49.51 | |
| Mizuho | 10 Apr 2025 | 60.00 (31.38%) | Beli | 42.55 |
| RBC Capital | 13 Mar 2025 | 52.00 (13.86%) | Pegang | 43.04 |
| Piper Sandler | 26 Feb 2025 | 70.00 (53.27%) | Beli | 48.50 |
| Scotiabank | 24 Feb 2025 | 73.00 (59.84%) | Beli | 51.28 |
| B of A Securities | 20 Feb 2025 | 65.00 (42.33%) | Beli | 49.51 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |